Vascular disrupting agents (VDAs) are the novel oncology drugs being developed to more specifically combat complex, life threatening cancer indications
Roots Analysis has announced the addition of “Vascular Disrupting Agents Market, 2021-2030” report to its list of offerings.
Despite multiple cancer treatment options, there is an evident unmet need for anti-cancer therapies with better efficacy and less toxicity. The vascular disrupting agents, which target the established tumor vasculature and disrupt blood flow to cancerous tissue, have garnered considerable interest as a novel anticancer therapeutic modality.
To order this 290+ page report, which features 110+ figures and 125+ tables, please visit https://www.rootsanalysis.com/reports/vascular-disrupting-agents-market.html
Key Market Insights
Currently, more than 120 vascular disrupting agents are in the development pipeline
Around 50% of the vascular disrupting agents are being evaluated in phase II clinical trials, while more than 5% are either marketed or in phase III of development. Examples of phase III drugs include Bavituximab (non-small cell lung cancer), Icaritin (hepatocellular carcinoma), NGR-TNF (malignant pleural mesothelioma), Padeliporfin (transitional cell cancer of renal pelvis and ureter), Plinabulin (non-small cell lung cancer, chemotherapy-induced neutropenia) and VB-111 (glioblastoma, recurrent platinum resistant ovarian cancer). Further, 35% molecules are in phase I trials.
Around 30 industry and non-industry players are engaged in the development of vascular disrupting agents
Around 40% of these firms are start-ups / small players (with less than 50 employees). It is also worth highlighting that, majority of the firms engaged in this domain (56%) are based in North America, followed by Asia Pacific (25%) and Europe (19%).